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AbstrACt
Objective The study aimed at analysing whether the 
‘Rule of Halves’ framework applies for diabetes care in the 
Danish healthcare system with high levels of accessibility 
and equity. The Rule of Halves states that only one-half of 
people with a particular chronic condition are diagnosed; 
one-half of those diagnosed get treatment, and one-half of 
treated achieve desired therapeutic goals.
Design The analysis is cross sectional based on available 
surveys, register data and clinical databases covering the 
adult population in Copenhagen. We analysed five levels 
of prevention and care including behavioural risk factors 
and biomarkers, prevalence of diagnosed and undiagnosed 
diabetes as well as how many received care according to 
guidelines and achieved relevant outcomes.
setting The study population is Copenhagen City with 
a population of 550 000 with 21 500 prevalent cases 
of diabetes. While the registers used cover the whole 
population, the surveys include 750 cases and the biobank 
data 365 cases.
Outcome measures Outcome measures are for each 
level of analysis: the prevalence of high-risk individuals, 
prevalence of undiagnosed and diagnosed diabetes, 
proportion receiving treatment and proportion achieving 
quality and treatment targets.
results We found that the ‘Rule of Halves’ framework 
raises relevant questions on how diabetes care works in 
a specific population, but the actual proportions found in 
Copenhagen are far from halves. Our analyses showed 
that 74% are diagnosed and among those who are 90% 
are receiving care. 40%–60% have achieved target 
levels of treatment in terms of HbA1c level and lipid 
levels. 80% have received eye and foot examinations in 
the last 2 years. 11% have retinopathy and 25% have 
macrovascular complications.
Conclusion Copenhagen is doing much better than 
halves, when it comes to diagnosis and providing 
treatment, whereas the Rule of Halves still prevails when 
it comes to treatment targets. There is thus still room for 
improvement.
IntrODuCtIOn   
In Denmark, the prevalence of registered 
type 2 diabetes was estimated to be 5.5% in 
2011,1 with an annual increase of 6% since 
2000. In addition, a considerable number is 
undiagnosed. To counter the rise in diabetes 
incidence and its complications it is neces-
sary to better understand which subgroups of 
the population are particularly vulnerable to 
diabetes. Further, among those who already 
have developed diabetes, it is important to 
identify patient groups not receiving the 
appropriate treatment.2 3 We applied a ‘Rule 
of Halves’ (RoH) approach to map out 
diabetes risk, diagnosis and treatment, and to 
identify vulnerable groups in the population 
of the City of Copenhagen in Denmark.
Despite the name, RoH is not a firm rule 
but rather a very context-dependent concep-
tual model, originally introduced in a survey 
of diabetes in New England in 1947.4 The 
RoH suggests that half the cases of a disease 
in a population stay undetected, half of those 
detected are untreated and half of those 
treated are not reaching treatment targets. 
The RoH was later found to apply for the 
British NHS in the 1980s for different chronic 
disorders including diabetes, hypertension 
strengths and limitations of this study
 ► Without a representative national health examina-
tion survey designed specific for performing a Rule 
of Halves analysis the combined use of postal sur-
veys with self-reported data, register data, clinical 
databases and samples from biobanks was used. It 
means that estimates within each level of Rule of 
Halves analysis can be compared, but comparisons 
across levels, where different sources are used, may 
not be valid.
 ► The registers and clinical databases used have full 
population coverage but reporting on some quality 
indicators might be biased due to non-reporting 
from primary care general practitioners.
 ► The surveys and biobanks suffer from 50% to 
60% non-participation rates, but comparisons with 
register data indicate low level of selection bias.
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and asthma.5 More recent studies from Europe indicate 
that ROH might still apply for hypertension in some 
areas6 while Finland, after ambitious cardiovascular 
disease (CVD) programmes, has improved to something 
like a rule of thirds.7 Today, the RoH is mostly found to 
apply in middle-income countries such as India where 
several studies on diabetes and hypertension have been 
done.8–10 The empirical findings for diabetes seem here 
more often to be a rule of two-thirds.8 The international 
initiative ‘Cities Changing Diabetes’ aims at improving 
diabetes control in several cities of high/middle-income 
countries and both RoH analyses and vulnerability assess-
ments are done to identify policy entry points and target 
groups for those efforts.11 This paper reports on the 
RoH analysis done for the City of Copenhagen, capital 
of Denmark.
What applied in the USA 70 years ago might not 
apply to today’s public health systems in a fast-changing 
global environment at different stages of nutritional and 
epidemiological transition. Even if the RoH does apply 
for some population groups and in some countries, the 
prevailing health inequalities even in the Scandinavian 
welfare states make it relevant to identify subgroups of the 
population where there might be inequalities in the rate 
of diagnoses and treatment. It has, for example, recently 
been shown that survival after diagnosis of diabetes is 
66% higher among high-income compared with low-in-
come groups.12 Also, increasing focus on prevention and 
early detection not least within the area of diabetes has 
made it imperative to address people with disease and to 
include high-risk populations in the RoH model.
The primary aim of this study was to determine whether 
an RoH applies for type 2 diabetes in Copenhagen. 
Further, we wished to identify inequalities in the occur-
rence, treatment and outcomes of type 2 diabetes in order 
to contribute to a better understanding of the social distri-
bution of diabetes, its causes and consequences in order 
to highlight inequalities that are not visible in the aver-
ages of the RoH model. The study might support health 
planning in Copenhagen City by identifying groups with 
unmet needs and test the more general question whether 
RoH applies for diabetes in a Nordic welfare state of today.
MethODs
Data sources
Since regular representative health examination surveys 
are not performed in Denmark, this RoH analysis was 
conducted based on existing quantitative data from four 
population and clinical registers, two waves of a repeated 
postal survey and one biobank on middle aged with 
health examinations.
The National Health Survey (NHS) is a repeated postal 
questionnaire survey conducted among a representative 
sample of citizens aged 16 or above. The Health Survey 
presents data on health, sickness and health behaviour. 
Data from the two waves of the survey conducted in 2010 
and 2013 were analysed. A total of 95 150 persons were 
invited in each wave and response rates were 52.3% and 
43.5%, respectively13.14 We used data from respondents 
living in the City of Copenhagen.
Copenhagen Ageing and Midlife Biobank (CAMB) is a 
Danish population-based cohort study, combining 
detailed life course information with measures of phys-
iological functioning and health.15 All cohorts included 
participants from the Greater Copenhagen area, but not 
specifically from the City of Copenhagen, and all partici-
pants were middle aged between 49 and 63 years in 2009–
2011. Of the 17 937 invited participants, 40% completed 
a postal questionnaire and underwent a health examina-
tion including body mass index (BMI) and blood samples 
including HbA1c.
National medical registers. The National Patient Register 
(LPR) covers all admissions and outpatient treatments 
at public somatic hospitals for the entire Danish popu-
lation, and includes information on diagnosis.16 The 
Register of Medicinal Product Statistics (LSR) contains 
information about sales of all prescribed medicinal prod-
ucts in Denmark.17 Data from the two registers are linked 
to demographic and socioeconomic data via Statistics 
Denmark. Data from the year 2011 were used for the anal-
yses, and limited to residents in the City of Copenhagen 
aged 16 or older.
The Danish Adult Diabetes Database (DVDD) is a nation-
wide clinical quality database on diabetes treatment. 
Results of yearly clinical assessments of patients diag-
nosed with type 1 and type 2 diabetes are reported to 
DVDD from hospital outpatient clinics and general 
practitioners (GP).18 It has been mandatory for hospital 
outpatient clinics to report since 2005, whereas data 
from GPs were reported gradually and voluntarily since 
2006. All patients with diabetes over 17 years of age who 
have had contact with a hospital outpatient clinic or a 
GP are eligible for inclusion in the DVDD. Coverage of 
cases treated in the secondary sector of outpatient clinics 
is 97%18 but still low from GPs. The coverage of clin-
ical data of those included is better than 90%.18 For the 
DVDD-based analyses in the present study, we defined 
‘the Capital area’ of Copenhagen according to Statistics 
Denmark’s definition, and therefore included patients 
with type 2 diabetes treated at GPs or outpatient clinics 
within the postal codes 1100–2920 and 3500. A total of 
25 315 persons with type 2 diabetes treated at clinics or 
GPs in the Capital area of Copenhagen were included in 
the analyses. DVDD was linked with the National Patient 
Register and the Cause of Death Register for identifica-
tion of complications. DVDD includes demographic data 
on age, sex and country of birth but no socioeconomic or 
educational status data. Table 1 gives an overview of the 
variables included from each of the four data sources.
Patient and public involvement. The study has not 
involved patients or the public but the results have been 
used by the health administration of the City of Copen-
hagen for planning a better diabetes prevention and 
care.
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Analyses
Five analytical levels (0-4) in the RoH analysis for diabetes 
in Copenhagen were assessed through the following 
analyses:
Level 0: The population at high risk of developing diabetes 
was assessed through prevalence (among those without 
diabetes) of risk factors, high diabetes risk score (defined 
by an adapted version of the Diabetes Risk Score based 
on age, sex, BMI, hypertension and physical activity19) 
or high-risk HbA1c level between 42 and 47 mmol/mol 
(6.0%–6.5%),20 using data from the National Health 
Survey (NHS) and the CAMB study.
Level 1: The population with diagnosed and undiagnosed 
diabetes was assessed using data from the NHP and CAMB 
study, estimating both the total population with diabetes 
(self-reported or HbA1c≥48 mmol/mol (6.5%))16 and 
the proportion with undiagnosed diabetes (defined as no 
self-reported diabetes but an HbA1c level of ≥48 mmol/
mol).
Level 2: The proportion of patients with type 2 diabetes 
receiving diabetes care was described using register data. 
Diabetes was defined as admission with primary diagnosis 
E10–E14 (International Classification of Diseases 10th 
Revision, ICD-10) in LPR or as having filled a prescrip-
tion for drugs with Anatomical Therapeutic Chem-
ical code A10 in LSR. To assess diabetes-specific care, the 
extent to which patients in the DVDD database received 
examinations for complications and had clinical markers 
assessed according to national guidelines was analysed. 
The Danish national guidelines suggest eye examinations 
every second year, foot examinations every year and yearly 
assessments of HbA1c, lipids and blood pressure.21
Level 3: The population achieving treatment targets was 
analysed using DVDD data and defined as those having 
well-regulated HbA1c levels (<53 mmol/mol), blood 
pressure (<130/80 mm Hg) and lipid levels (low-density 
lipoprotein (LDL) cholesterol <2.5 mmol/L in patients 
without existing complications, and <1.8 mmol/L for 
patients with existing complications). Dyslipidaemia, 
hypertension and elevated HbA1c levels are known risk 
factors for development of diabetes complications, and 
the above cut-off levels for blood pressure, LDL choles-
terol and Hba1c levels are defined in national guidelines 
for treatment of type 2 diabetes.21 Further, based on data 
from the CAMB study the proportion achieving treatment 
targets was estimated as those with self-reported diabetes 
that had measured HbA1c<53 mmol/mol.
Level 4: The population achieving desired treatment outcomes 
was defined as those without microvascular or macrovas-
cular complications. The part of the population with type 
2 diabetes that experienced macrovascular complications 
was assessed with data from the LPR register (admission 
with ischaemic heart disease (ICD-10: I20–I25), periph-
eral arterial disease (ICD-10: I70, E11.5, E13.5, E14.5) 
or cerebrovascular disease (ICD-10: I60–I69, G45)), 
the Health Profile (self-reported myocardial infarction, 
angina pectoris or stroke) and DVDD (ischaemic heart 
disease (ICD-10: I20–I25); peripheral artery disease (ICD-
10: I70–I71, I74–I75, I73.9); heart failure (ICD-10: I50–
I51, I11–I13); stroke (ICD-10: I63–I66, I69); amputations 
(ICD-10: Z89.4–Z89.7); and other CVD codes (ICD-10: 
E10.6, E11.6, E13.6, E14.6)). Microvascular complica-
tions were defined as occurrence of severe retinopathy 
(ICD-10: H33–H35, H43); diabetic kidney disease (ICD-
10: E10.2, E11.2, E13.2, E14.2, DN18.0, DN18.8, DN18.9, 
Z49.2, Z94.0, Z99.2); and neuropathy (ICD-10: E104, 
E114, E134, E144, DD62–63), and assessed based on the 
DVDD database.
To assess the distribution of diabetes and possible 
inequalities in diabetes occurrence and treatment, a list of 
physiological and behavioural risk factors, demographic 
and socioeconomic variables and information regarding 
health prevention were included in the analyses.
For level 0 to level 3 in the RoH analysis, propor-
tions were calculated to characterise the overall popu-
lation prevalence of diabetes outcomes. To determine 
the importance of different demographic, clinical and 
Table 1 Physiological, behavioural, demographic and 
socioeconomic factors included in the analyses
Health 
Survey
Register 
data DVDD CAMB
Physiological and behavioural risk factors
  BMI (calculated 
from weight and 
height)
x* x† x†
  Physical activity x* x*
  Smoking status x* x* x*
  Blood pressure x*‡ x† x†
  Cholesterol x† x†
  Diabetes diagnosis x* x§ x† x*
Demographic and socioeconomic factors
  Age x§ x x§ x§
  Sex x§ x x§ x§
  Ethnicity x§ x x§
  Education x§¶ x¶ x*¶
  Employment status x§ x x*
Screening service
  Date of last eye 
examination
x
  Date of last foot 
examination
x
*Self-reported.
†Measured values.
‡In the Health Profile, participants only report whether or not they 
have high blood pressure.
§Based on linkage with register data.
¶Educational level was grouped into: low education defined as 
primary or secondary school, semiskilled or skilled worker; medium 
education defined as up to 4 years’ theoretical education; and high 
education defined as more than 4 years’ theoretical education.
BMI, body mass index; CAMB, Copenhagen Aging and Midlife 
Biobank; DVDD, Danish Adult Diabetes Database. 
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socioeconomic factors, the descriptive measures were 
stratified and multivariate logistic regression analyses 
were performed with diabetes outcomes as the depen-
dent variable. In level 4, differences in crude incidence 
rates based on incident events and person-years at risk 
were used to calculate the incidence of microvascular and 
macrovascular complications, and Cox regression models 
with adjustment for covariates were used to compare 
differences in incident complications across subgroups.
Analyses were performed using SAS for Windows 
(V.9.3) or Stata/IC V.12.1 for Windows. Survey analysis 
techniques were applied for the analyses of the NHS data 
weighted for non-response using a population weight 
calculated by Statistics Denmark.22
results
level 0: population at risk
The prevalence of type 2 diabetes risk factors and pre-di-
abetes across demographic and socioeconomic groups 
is shown in table 2. Overall, 6.6% of the CAMB popula-
tion have HbA1c levels considered to be a high risk for 
developing diabetes and 12.7% of the population in 
NHP have a high diabetes risk score. For the three risk 
factors examined, the results show that 10%–15% of the 
population are obese, 15%–30% are physically inactive 
and 23%–28% smoke. With regard to demographic and 
socioeconomic factors, higher prevalence of diabetes 
risk factors is found among males, people with higher 
age, lower education and no employment. For ethnicity, 
the pattern is less clear; people with a non-western back-
ground have higher rates of obesity and physical inac-
tivity, but more people with a western background smoke. 
Finally, those living with others or having children living 
at home have lower prevalence of diabetes risk factors 
and lower diabetes risk score. The results of the regres-
sion analyses also show that especially low education and 
not being employed are related to a higher diabetes risk 
score and pre-diabetic HbA1c level (table 2). Analyses 
of preventive services based on NHP data showed that 
35%–45% of the population with high risk of diabetes 
received information regarding prevention and 9%–13% 
accepted offers to participate in preventive interventions, 
compared with 13%–18% and 2%–4% of those with low 
diabetes risk (results not shown).
level 1: population with diagnosed or undiagnosed diabetes
There are clear socioeconomic differences in the self-re-
ported prevalence of diabetes (see table 3). Figures from 
the NHS show a prevalence of 5.8% among low educated 
compared with 1.3% among high educated. Among the 
not employed the prevalence is 10.4%. Based on CAMB 
data on middle aged, the overall prevalence of diabetes 
(self-reported or measured HbA1c of ≥48 mmol/mol) was 
4.2%. From that data we can further estimate a proportion 
of undiagnosed diabetes of 1.1% defined as the propor-
tion with HbA1c of ≥48 mmol/mol that did not report 
diabetes in the interview. This means that 26% (1.1/4.2) 
out of the total of 4.2% are not diagnosed. Further, if the 
proportion of diagnosed diabetes from CAMB data (74%) 
is assumed to apply to all age groups of the adult popu-
lation and is combined with the self-reported diabetes 
prevalence from NHS (3.8%) which comprises a broader 
age range, then the diabetes prevalence in Copenhagen 
would be 3.8/0.74=5.1%.
level 2: population receiving diabetes care
Among the 25 316 people in the Capital area with type 2 
diabetes in DVDD, 13 027 people had minimum 2 years’ 
follow-up time and a valid date of eye examination. Of these, 
more than 80% had an eye examination within 2 years of 
the last clinical examination. There were no significant 
differences in the odds for having eye screening across 
sex, age groups or region of origin (table 4). Of those 
people with minimum 1 year follow-up time and a valid 
date of last foot examination, 81.4% had a foot examina-
tion within a year of the last clinical examination. Women 
and older age groups were more likely to receive yearly 
foot examination, whereas migrants from the Middle East 
and North Africa were less likely compared with Danish 
born. Among those with minimum 1 year follow-up time 
and a valid date of last HbA1c assessment, more than 90% 
had an HbA1c assessment within the last year of last clin-
ical examination. A total of 12 412 patients were included 
in the analyses of blood pressure assessment and almost 90% 
were treated according to national guidelines.21 Young 
people and migrants from South and North America and 
Oceania were less likely to have blood pressure assess-
ment, but still >85% of the patients in these subgroups 
had an annual assessment.
Lipids were assessed in close to 80% of patients according 
to national guidelines. Again, young people and migrants 
from Europe were less likely to receive assessment.
level 3: population achieving treatment targets
Based on data from the DVDD database, the proportion 
of patients with type 2 diabetes whose clinical values were 
within the national treatment targets in 2012 is shown in 
table 5. Overall, around 55% of the patients with a valid 
measurement had an HbA1c level within the national 
treatment target. This was the case for around 60% for 
LDL cholesterol, but only close to 40% for blood pres-
sure. Adjusted models showed that men, young and 
middle-aged people and migrants were less likely to 
be within the national treatment target for HbA1C, 
compared with women, older people and native Danish 
born. For LDL cholesterol, there was a similar pattern, 
except for men who were more likely to be within the 
treatment target. For blood pressure, men were less likely 
to be within treatment target, whereas migrants and older 
age groups were more likely to be within treatment target 
compared with their respective reference groups.
level 4: population achieving desired outcomes
In total, 40.3% of the people with type 2 diabetes in the 
Capital area who were alive and followed in DVDD as 
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of 31 December 2012 had some type of complication. 
The prevalence of any complications among patients 
within treatment targets in 2012 was 30.3% for HbA1c, 
42.6% for LDL cholesterol and 41.6% for blood pres-
sure (results not shown). Based on these results and the 
overall prevalence of any complications among people 
with type 2 diabetes in the Capital area, approximately 
60% of the people within treatment targets were without 
complications.
Based on register and survey data, respectively 11.4% 
and 24.8% of the population with diabetes had macro-
vascular disorders. The risk of macrovascular complica-
tions increased with age and was higher among males and 
those with no employment (results not shown). Based on 
data from DVDD, 28.5% of the population in the Capital 
area had a diagnosis of CVD at some point following their 
diabetes diagnosis. The overall incidence rate for CVD in 
patients with type 2 diabetes was 57.4 per 1000 person-
years in the Capital area, and with marked differences 
between sex and age groups (table 6). An estimated 11.3% 
had a retinopathy and the overall incidence rate of reti-
nopathy was 16.5 per 1000 person-years. Migrants from 
the Middle East and North Africa, and older people had 
a higher risk of developing severe retinopathy compared 
with native-born Danes and middle aged, respectively. For 
diabetic kidney disease, 18.3% had a diagnosis and the 
incidence rate was 18.5 per 1000 person-years. Men, older 
people and migrants from Europe were at increased risk 
of developing diabetic kidney disease compared with 
reference groups. Finally, 18.2% had a neuropathy diag-
nosis following their diabetes diagnosis, and the overall 
incidence rate was 17.7 per 1000 person-years. The strat-
ified and adjusted analyses showed significantly higher 
rates among men and age was also a risk factor.
DIsCussIOn
The results of our analyses show that the RoH levels do 
not generally apply for diabetes in Copenhagen; on most 
levels Copenhagen is doing better than simple halves. 
Overall, the results indicate that 10% of the population 
are at high risk of developing diabetes and 4.2%–5.1% 
have diabetes including the 1.1% we found to be undi-
agnosed cases. That is a slightly lower prevalence than 
we mentioned above for Denmark,1 but Copenhagen 
has both a younger and more well-educated population 
which might explain the difference. Three-quarters of the 
diabetes population were diagnosed. Preliminary find-
ings from other Danish population-based samples have 
found similar levels with approximately one-third of cases 
undiagnosed.23 Around 80%–90% of the patients diag-
nosed with diabetes received complications screening 
and clinical assessments according to national guidelines, 
and between 40% and 60% achieved treatment targets for 
HbA1c, cholesterol and blood pressure.
Our results show that there are major demographic 
and socioeconomic differences in the prevalence of risk 
factors, and occurrence and treatment of diabetes. High 
risk of diabetes was especially prevalent among those with 
low education and no employment. The latter is partly 
because they might be out of work due to their diabetes 
and complications. Obesity and physical inactivity were 
more prevalent among people with non-western back-
ground, whereas this was not the case for smoking. No 
socioeconomic data were available for the clinical data 
concerning the quality of treatment and prevalence 
of complications. With regard to ethnic differences, 
we found that men and migrants form the Middle East 
and Africa were less likely to receive foot examinations 
or have well-regulated HbA1c, and that some migrant 
groups scored high on microvascular complications, but 
the ethnic differences were often not large enough to 
be verified. The DVDD study does not include data on 
patient’s socioeconomic position, but recent studies from 
Denmark have shown clear socioeconomic inequalities 
in diabetes care utilisation,24 regulation,25 complications 
and survival.12
The RoH concept includes both a framework for 
analysing proportions diagnosed, treated and achieving 
treatment targets and a rule about that this proportion 
usually will be halves. While we find the framework useful, 
the Rule of Halves clearly does not apply for diabetes in 
Copenhagen. Studies on both diabetes and hypertension 
have shown that the actual proportions are very context 
dependent and sensitive to differences in policies that 
influence coverage and quality.7–10 The large inequalities 
found for diabetes occurrence and consequences in an 
otherwise comparatively equal welfare state show the rele-
vance of examining the above-mentioned proportions in 
different groups.
Our study is the first to examine diabetes in an urban, 
European contemporary setting, using the RoH as a 
guiding framework. Several high-quality data sources were 
used to describe five analytical levels, from being at risk to 
Table 3 Level 1: Proportions (%) of self-reported, 
diagnosed and undiagnosed diabetes
NHS (16+ 
years) CAMB (49–63 years)
Self-
reported 
diabetes 
Self-reported 
diabetes or 
HbA1c≥48 
(mmol/mol) 
No self-
reported 
diabetes but 
HbA1c≥48 
(mmol/mol) 
All 3.8 4.2 1.1
Education* 
  Low 5.8 5.2 1.5
  Medium 2.3 3.5 0.7
  High 1.3 2.2 0.3
Employment* 
  Employed 1.6 3.6 0.9
  Not employed 10.4 10.2 3.0
*The differences across educational level and employment are all 
significant, p<0.01.
CAMB, Copenhagen Aging and Midlife Biobank; NHS, National 
Health Survey. 
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development of complications. However, when drawing 
conclusions based on the results presented here, some 
methodological aspects of the analyses must be noted, as 
they might have affected the results. First and foremost, it 
is important to note that different data sources have been 
used for the different levels of the RoH analysis. Thus, 
the results from each level are not directly comparable, 
since the populations analysed were different in terms 
of background variables including age. It is possible that 
the prevalence of diagnosed and undiagnosed diabetes 
is underestimated due to the general under-reporting in 
surveys and the assumption that the proportion of diag-
nosed applies in all ages, when it is most likely higher 
among people aged above 64, who were not included in 
the CAMB study.
Related to treatment targets, the estimate of well-reg-
ulated HbA1c based on CAMB data was higher than the 
estimate based on data from the DVDD database (level 4). 
This might be explained by the age group included in the 
CAMB study and/or the selection inherent in who partici-
pates in research examinations. Also, the exact geograph-
ical definition of Copenhagen differed between the two 
data. Further, we found a rather large difference in popu-
lation prevalence of macrovascular complications based 
on data from the national registers versus the NHS. This 
is most likely due to many patients with mild disorders 
not being treated in the hospital system, but in primary 
care, and thus not included in the registers. The estimate 
from survey data was in agreement with estimates from 
the DVDD database, which include data from outpatient 
clinics and primary care units.
Some of the information from the NHS and CAMB was 
based on self-report, which might cause some degree of 
misclassification. The Capital Region has performed anal-
ysis of the coverage of self-reported disease in the Health 
Profile compared with data from registers. For diabetes, 
73% of those detected through survey and registers 
together were identified when using survey data only.26 
Data from the national Danish registers cover the entire 
population. However, not one register covers all health-re-
lated contacts: LPR includes only contacts with public 
hospitals, but private hospitals represent only a very small 
proportion of contacts. LSR includes all prescribed drugs 
including those made by doctors in primary care and 
private care. Primary care data are included in the DVDD, 
but since this reporting was not mandatory before 2013, 
the DVDD database does not contain complete informa-
tion from primary care, and the vast majority of patients 
in DVDD are treated in hospital outpatient clinics. It is 
uncertain to what extent the GPs reporting to DVDD 
comprise a representative sample of GPs in Denmark. We 
might therefore underestimate the rates of complications 
if those GPs not reporting to DVDD have higher rates, but 
we expect that there are higher rates among those treated 
in hospitals.
Table 5 Level 3: Proportion and OR for patients with type 2 diabetes in the Greater Copenhagen area to be within national 
treatment targets on HbA1c, LDL cholesterol and blood pressure. Based on DVDD data
Treatment targets
HbA1c<53 mmol/mol
(n=14 121)
LDL cholesterol<2.5 mmol/L
(n=14 171)
Blood 
pressure<130/80 mm Hg 
(n=12 511)
% OR (95% CI) % OR (95% CI) % OR (95% CI)
Overall 55.7 60.6 39.4
Sex
  Men 54.9 0.91 (0.84 to 0.97) 62.4 1.20 (1.12 to 1.28) 38.3 0.91 (0.85 to 0.98)
  Women 56.8 Ref 58.1 Ref 40.7 Ref
Age (years)
  17–44 47.1 0.95 (0.80 to 1.12) 45.6 0.70 (0.59 to 0.82) 42.7 1.13 (0.95 to 1.35)
  45–64 50.5 Ref 56.6 Ref 38.6 Ref
  65+ 60.2 1.33 (1.23 to 1.42) 64.6 1.38 (1.29 to 1.49) 39.6 1.09 (1.01 to 1.18)
Region of origin
  Denmark 59.7 Ref 62.0 Ref 38.4 Ref
  Europe 48.8 0.65 (0.56 to 0.76) 57.0 0.84 (0.72 to 0.97) 37.2 0.95 (0.80 to 1.12)
  Sub-Saharan Africa 48.2 0.70 (0.48 to 1.02) 50.9 0.75 (0.51 to 1.10) 46.0 1.39 (0.93 to 2.06)
  Middle East and North 
Africa
36.5 0.42 (0.38 to 0.47) 56.1 0.90 (0.81 to 1.01) 45.1 1.33 (1.19 to 1.49)
  Asia 44.4 0.57 (0.45 to 0.72) 52.1 0.76 (0.60 to 0.95) 38.5 1.00 (0.78 to 1.29)
  America and Oceania 50.0 0.69 (0.40 to 1.18) 50.9 0.65 (0.38 to 1.12) 38.3 1.01 (0.56 to 1.82)
DVDD, Danish Adult Diabetes Database; LDL, low-density lipoprotein. 
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Open access 
COnClusIOn
The RoH model raises important questions about the 
proportions diagnosed, treated and reaching targets but 
any Rule of Halves is not supported in this study. Our anal-
yses show that Copenhagen is doing better than halves, 
especially when it comes to diagnosing diabetes and 
providing treatment, whereas the proportions achieving 
treatment targets were closer to halves. Thus, there is still 
room for improvement.
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